RNA, U6 small nuclear 17, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-17P profile across patient tissues and cancer cell-line models. RNU6-17P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, RNU6-17P is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, RNU6-17P RNA expression shows 3,105 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, and STAD as cancer lineages where RNU6-17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-17P survival associations across molecular data types. RNU6-17P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-17P RNA expression–survival associations across cancer types. High RNU6-17P expression shows unfavorable associations in TGCT, LIHC, KIRC, READ, UVM and BLCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for RNU6-17P RNA expression.
This table summarizes RNU6-17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-17P shows higher tumor expression in STAD. The STAD box plot shows higher RNU6-17P RNA expression in tumor versus normal tissue (log2 FC = +0.441, t-test p = .035).
This table shows molecular features associated with RNU6-17P in patient tissues and cancer cell lines. In patient samples, RNU6-17P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
